ACLX

Arcellx, Inc. (NASDAQ:ACLX) is a clinical-stage biotechnology company founded in 2014 and headquartered in Gaithersburg, Maryland. Originally incorporated as Encarta Therapeutics, the company changed its name to Arcellx in January 2016 and went public in February 2022. Arcellx focuses on developing innovative immunotherapies for patients with cancer and other incurable diseases, with a particular emphasis on engineered cell therapies and protein-based treatments for blood cancers and solid tumors.